RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of ...

Psychedelic industry faced setbacks, cannabis was almost rescheduled and overdose deaths dropped — but not for all ...

There is hope for a new 5 by 3 global target of getting 5 million people on long-acting PrEP to prevent HIV by 2030.

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

As the year winds down, we wanted to take a look back at some of the top scientific discoveries that happened in 2024. From ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

There's no question that the world has a trash problem. E-waste is no exception. The 2024 Global E-waste Monitor, published ...

Several giant US and international groups focused on fighting HIV and AIDS on Tuesday unveiled a plan to swiftly provide ...

Lenacapavir, a preventive HIV drug, could become accessible in low-income countries by 2026. Efforts spearheaded by global ...

By 2025, a new HIV preventive drug, lenacapavir, could be available to the world's poorest regions. The Global Fund aims to ...